Loading patent…
AssigneeKymab Limited
InventorsAnthea NEWTON, Cintia Cristina PALU, Sonia QUARATINO, Richard Charles Alfred SAINSON, Cecilia DEANTONIO, Matthew Stephen WAKE
Estimating the term…
This invention relates to compositions and methods for the treatment of cancer, in particular difficult-to-treat cancers. More specifically, the present invention relates to compositions and methods for the treatment of PD-L1 negative or PD-L1 low expressing cancers using a modulator of ICOS, such as an anti-ICOS antibody, either alone or in combination with other agents, such as an anti-PD-L1 antibody.
A method of treating cancer in a patient, wherein the patient has a PD-L1 negative tumour or a tumour with low PD-L1 expression, comprising administering to the patient a modulator of ICOS.
2-9. (canceled)
12-17. (canceled)
19-21. (canceled)
24-29. (canceled)
(canceled)
34-36. (canceled)
A method of treating cancer in a patient comprising administering to the patient a modulator of ICOS, wherein:
(canceled)
A method of treating cancer in a patient who has previously received treatment for the cancer, wherein the previous treatment for the cancer was administration of a PD-L1 inhibitor and the patient did not respond to the previous treatment or ceased responding to the previous treatment, and wherein the patient has a PD-L1 negative tumour or a tumour with low PD-L1 expression, comprising administering to the patient a modulator of ICOS.
Dependencies are inferred from the claim text.